← Back to IMVT

Immunovant, Inc. - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 06/08/2026Dec 2025Filed 06/02/2026Sep 2025Filed 06/02/2026Jun 2025Filed 06/08/2026Dec 2024Filed 06/02/2026Sep 2024Filed 06/02/2026Jun 2024Filed 06/02/2026Dec 2023Filed 06/02/2025
−$153−$111−$127−$121−$111−$109−$87−$51
−$0.75−$0.61−$0.73−$0.71−$0.76−$0.74−$0.60−$0.36
206182174171147146146145

Trend

Net income

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.